文献速递肝病消化道肿瘤与早癌

MASLD与肝细胞癌及不良肝脏结局的家族性共聚集:全国性多代队列研究

Familial coaggregation of MASLD with hepatocellular carcinoma and adverse liver outcomes: Nationwide multigenerational cohort study.
PubMed 文献 · J Hepatol · 2023-08-28

这项全国性多代队列研究纳入经活检证实的MASLD患者的家庭成员及匹配的普通人群对照,计算肝细胞癌(HCC)、主要不良肝脏结局等调整风险比。中位随访17.6年,MASLD患者一级亲属的HCC发生率高于对照一级亲属(13 vs 8/10万人年;aHR 1.80,95%CI 1.36-2.37),主要不良肝脏结局和肝病相关死亡率也升高,但绝对风险较低。

要点

  • MASLD患者一级亲属的HCC发生率高于对照一级亲属(13 vs 8/10万人年;aHR 1.80,95%CI 1.36-2.37)。
  • MASLD患者一级亲属的主要不良肝脏结局和肝病相关死亡率均高于对照一级亲属。
  • MASLD患者配偶的主要不良肝脏结局和肝病相关死亡率升高,但HCC风险未达统计学显著。

核心结论

  • 经活检证实的MASLD患者家庭中存在不良肝脏相关结局的明显家族聚集,HCC、进展性肝病和肝病相关死亡的相对风险较高,但绝对风险较低。

研究设计与样本

  • 全国性多代队列研究,纳入1969-2017年瑞典所有经活检证实MASLD成人的家庭成员及匹配的普通人群对照。
  • 识别MASLD患者一级亲属38,018名和配偶9,381名,以及对照一级亲属197,303名和对照配偶47,572名。
  • 采用Cox比例风险模型计算HCC、主要不良肝脏结局、肝病相关死亡率、肝外癌症和非肝相关死亡率的调整风险比(aHR)。

主要发现

  • 中位随访17.6年,MASLD患者一级亲属的HCC发生率为13/10万人年,高于对照一级亲属的8/10万人年(aHR 1.80,95%CI 1.36-2.37)。
  • 肝纤维化/肝硬化患者的一级亲属HCC风险进一步升高(aHR 2.14,95%CI 1.07-4.27;异质性P=0.03)。
  • MASLD患者一级亲属的主要不良肝脏结局发生率为73/10万人年,高于对照一级亲属的51/10万人年(aHR 1.52,95%CI 1.36-1.69)。
  • MASLD患者一级亲属的肝病相关死亡率为20/10万人年,高于对照一级亲属的11/10万人年(aHR 2.14,95%CI 1.67-2.74)。
  • MASLD患者配偶的主要不良肝脏结局发生率为86/10万人年,高于对照配偶的74/10万人年(aHR 1.23,95%CI 1.01-1.51);肝病相关死亡率为25/10万人年,高于对照配偶的19/10万人年(aHR 1.93,95%CI 1.15-3.23);HCC风险未达统计学显著(aHR 1.43,95%CI 0.87-2.35)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Metabolic dysfunction-associated steatotic liver disease (MASLD; formerly NAFLD) is the fastest growing cause of hepatocellular carcinoma (HCC) worldwide. However, whether family members of individuals with MASLD also share an increased risk of developing HCC is unknown. METHODS: This nationwide multigenerational cohort study involved family members of all Swedish adults diagnosed with biopsy-proven MASLD (1969-2017), and matched general population comparators. Using the Swedish Multi-generation Register, we identified 38,018 first-degree relatives (FDRs: parents, siblings, offspring) and 9,381 spouses of patients with MASLD, as well as 197,303 comparator FDRs and 47,572 comparator spouses. We used Cox proportional hazards models to calculate adjusted hazard ratios (aHRs) for HCC, major adverse liver outcomes (cirrhosis, decompensated liver disease or liver transplantation), liver-related mortality, extrahepatic cancer, and non-liver-related mortality. RESULTS: Over a median of 17.6 years, the rate of the primary outcome HCC was higher in MASLD FDRs vs. comparator FDRs (13 vs. 8/100,000 person-years [PY]; aHR 1.80, 95% CI 1.36-2.37). The HCC risk was further increased in FDRs of individuals with liver fibrosis/cirrhosis (aHR 2.14, 95% CI 1.07-4.27; PHeterogeneity = 0.03). MASLD FDRs also had higher rates of major adverse liver outcomes (73 vs. 51/100,000 PY; aHR 1.52, 95% CI 1.36-1.69) and liver-related mortality (20 vs. 11/100,000 PY; aHR 2.14, 95% CI 1.67-2.74). MASLD FDRs with any concomitant chronic liver condition experienced accelerated progression of liver disease (aHR 1.47, 95% CI 1.29-1.67). MASLD spouses were at higher risks of major adverse liver outcomes (86 vs. 74/100,000 PY; aHR 1.23, 95% CI 1.01-1.51) and liver-related mortality (25 vs. 19/100,000 PY; aHR 1.93, 95% CI 1.15-3.23), but not of HCC (aHR 1.43, 95% CI 0.87-2.35). CONCLUSIONS: There is distinct familial clustering of adverse liver-related outcomes in families of individuals with biopsy-proven MASLD, with higher relative risks of HCC, progressive liver disease, and liver-related mortality, but absolute risks are low. IMPACT AND IMPLICATIONS: Metabolic dysfunction-associated steatotic liver disease (MASLD; formerly termed NAFLD) clusters in families with high genetic susceptibility and shared environmental risk factors, but the risks of developing hepatocellular carcinoma and other major liver-related outcomes in family members of individuals with MASLD are largely unknown. This large nationwide multigenerational cohort study involving family members (first-degree relatives and spouses) of individuals with biopsy-proven MASLD and of matched general population comparators found slightly increased risks of hepatocellular carcinoma in first-degree relatives, and of developing cirrhosis and liver-related mortality in all family members of individuals with biopsy-proven MASLD. The findings of this study provide large-scale evidence to inform clinical practice guidelines for recommendations on the early identification of individuals at higher risk of liver-related morbidity and mortality.

来源:J Hepatol,查看原文。版权归原作者所有。

引用

  1. Ebrahimi F, Hagström H, Sun J, et al. Familial coaggregation of MASLD with hepatocellular carcinoma and adverse liver outcomes: Nationwide multigenerational cohort study. J Hepatol. 2023. PMID: 37647992. doi:10.1016/j.jhep.2023.08.018

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。